Laboratorios Farmaceuticos Rovi, S.A.

LABFFOTCHealthcare● Active

$90.61

+$0.00(+0.00%)

Market Cap$4.6B

P/E Ratio—

52W High$90.61

52W Low$90.61

Avg Volume53.6

Open$90.61

Beta0.22

Overview

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LABFF · free cash flow · updated Jun 9, 2026

Core FCF metrics

LABFF · FCF · TTM · margin & CAGR

Free cash flow was $120.1M for FY2025 (fiscal year ending 2025-12-31), up 57.9% year-over-year The FCF margin was 16.2%. Five-year CAGR stands at +75.7%.

FY2025 Free Cash Flow$120.1M▲ +57.9% YoY

Trailing 12M (TTM)$114.8Mtrailing 4 quarters sum

FCF Margin16.2%$120.1M ÷ revenue

3-Year CAGR-13.6%FY2022 → FY2025

5-Year CAGR+75.7%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LABFF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$185.3M(65M)$120.1M▲ +57.9%16.2%

FY2024$138.3M(62M)$76.1M▲ +31.0%10.0%

FY2023$113.2M(55M)$58.1M▼ 68.8%7.0%

FY2022$237.6M(51M)$186.2M▲ +71.6%22.8%

FY2021$149.4M(41M)$108.5M▲ +1410.3%16.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LABFF · P/FCF · FCF yield · FCF per share

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) trades at a FCF yield of 3.84% and a price-to-free-cash-flow ratio of 40.5x. FCF per share stands at $2.24, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.84%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.24

TTM FCF ÷ Shares Outstanding

Price / FCF

x40.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x26.2

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LABFF · cash flow statement · operating / investing / financing

For FY2025, Laboratorios Farmaceuticos Rovi, S.A. generated $185.3M in operating cash flow and spent 65M in capital expenditures, yielding $120.1M in free cash flow.

Operating Activities

+$185.3M

Cash from core business operations

2025-12-31

Investing Activities

−$67.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$47.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($185.3M) − |CapEx| (65M) = FCF ($120.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LABFF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Laboratorios Farmaceuticos Rovi, S.A.YOU

LABFF

$120.1M+57.9%16.2%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) reported free cash flow of $120.1M for FY2025 (fiscal year ending 2025-12-31), up 57.9% year-over-year. The FCF margin was 16.2%.

Based on available data, Laboratorios Farmaceuticos Rovi, S.A. has maintained positive free cash flow for at least 11 fiscal year(s). FCF peaked at $186.2M in FY2022. The 5-year CAGR stands at +75.7%.

Laboratorios Farmaceuticos Rovi, S.A.'s FCF yield is 3.84% and price-to-FCF ratio is 40.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LABFF free cash flow · 8 questions

Laboratorios Farmaceuticos Rovi, S.A. free cash flow was $120.1M for FY2025, up 57.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $114.8M.

LABFF free cash flowLABFF FCFLABFF FCF 2025LABFF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Laboratorios Farmaceuticos Rovi, S.A. · Laboratorios Farmaceuticos Rovi, S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026